Among 42 patients living with diagnosed generalized myasthenia gravis, those who also had the subtype thymoma-associated myasthenia gravis (n = 22) demonstrated reductions in their Myasthenia Gravis Activities of Daily Living (MG-ADL) and need for corticosteroids by week 12 of treatment with eculizumab.
New study findings from a joint investigation at 5 research centers in Shanghai, China, in Therapeutic Advances in Neurological Disorders1 explain the efficacy and safety of eculizumab. The monoclonal antibody targets the complement protein C5 and prevents it from cleaving into C5a and C5b, thereby inhibiting the membrane attack complex.2,3
Patients in this real-world analysis were treated between June 2023 and June 2024 in 5 neuromuscular diagnostic centers in East, South, and West China for their thymoma-associated…